Ranbaxy spinout gets $6.5M for N.J.-based generics biz
Bionpharma just raised $6.5 million, according to a regulatory filing - on top of about $31 million raised last year.
Bionpharma just raised $6.5 million, according to a regulatory filing - on top of about $31 million raised last year.
Ranbaxy‘s generic pharmaceuticals business in the U.S. has been suspended until it can correct violations at its factories in India and the United States that triggered a federal injunction. Under the terms of a settlement reached with the U.S. Department of Justice, which described its investigation of the company as “groundbreaking,” the company is to […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.